Entries by admin@ask-gene.com

AskGene Announces Submission of IND to FDA for ASKG915

Camarillo, California, November 21st, 2022 – AskGene Pharma Inc. is pleased to announce the submission of an Investigational New Drug (IND) application for ASKG915 to the United States Food and Drug Administration (FDA).  ASKG915 is a recombinant human anti-PD-1 monoclonal antibody and IL-15 prodrug fusion protein for oncology indications. Jian-Feng (Jeff) Lu, Ph.D., CEO of […]

AskGene Presents Latest Results on ASKG315 and ASKG915 at SITC 2022

Camarillo, California, November 15th, 2022 – AskGene presented the pre-clinical results of ASKG315 (IL-15 prodrug) and ASKG915 (PD-1/IL-15 prodrug) at the Society for Immunotherapy of Cancer’s (SITC) 37th Annual Meeting in Boston on November 8 – 12, 2022.  For ASKG315 phase I clinical study design was also presented.  The two posters were: #1101, Chunxiao Yu et […]

AskGene Announces Appointment of Chief Medical Officer and VP of Preclinical & Clinical Pharmacology

Camarillo, California, August 19, 2022 – AskGene Pharma Inc. (AskGene) today announced the appointment of Barbara Hickingbottom, J.D., M.D. as Chief Medical Officer and Matt Hsu, Ph.D. as VP of Preclinical and Clinical Pharmacology.  Dr. Hickingbottom will be responsible for leading the global clinical development of AskGene, including pipeline strategy, clinical development plans and operations, […]

AskGene Pharma Announces First Development Milestone in License Agreement with AffaMed for the Development of ASKG712 in Retinal Disease

Camarillo, California, June 20, 2022 – AskGene Pharma Inc., an innovative clinical-stage biotech company, announces that its partner AffaMed has dosed the first patient in its US Phase 1 study of ASKG712 (AM712), a novel proprietary bispecific biologic molecule blocking both vascular endothelial growth factor (VEGF) and angiopoietin-2 (Ang-2) for the treatment of retinal diseases. The study […]